BEONE MEDICINES(06160.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at USD 464.36 million, YoY increase of 385.79%
August 05, 2026, BEONE MEDICINES(06160.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 3.22 billion, increased by 32.31% YoY; Net Profit stood at USD 464.36 million, YoY increase of 385.79%; Profit Attributable to Shareholders stood at USD 464.36 million, YoY increase of 385.79%.
In terms of profitability, BEONE MEDICINES Gross Profit changed from USD 2.1 billion in the same period last year to USD 2.88 billion in the current period, increased by USD 773.79 million; gross profit margin changed from 86.45% in the same period last year to 89.38% in the current period, increased by 2.93 percentage points; net profit changed from USD 95.59 million in the same period last year to USD 464.36 million in the current period, increased by USD 368.77 million; net profit margin changed from 3.93% in the same period last year to 14.43% in the current period, increased by 10.5 percentage points.
In terms of earnings quality, BEONE MEDICINES Operating Profit changed from USD 98.99 million in the same period last year to USD 574.95 million in the current period, increased by USD 475.96 million; Operating Profit Margin changed from 4.07% in the same period last year to 17.86% in the current period, increased by 13.79 percentage points; Net Cash Flow from Operating Activities changed from cash inflow of USD 307.68 million in the same period last year to cash inflow of USD 664.16 million in the current period, increased by USD 356.48 million; Ratio of Net Cash Flow from Operating Activities to Total Operating Revenue changed from 12.65% in the same period last year to 20.64% in the current period, increased by 7.99 percentage points.
In terms of financial soundness, BEONE MEDICINES Debt-to-Asset Ratio changed from 40.14% in the same period last year to 43.61% in the current period, increased by 3.48 percentage points; Total Equity changed from USD 3.77 billion in the same period last year to USD 5.174 billion in the current period, increased by USD 1.4 billion; Cash and Cash Equivalents changed from USD 2.786 billion in the same period last year to USD 5.281 billion in the current period, increased by USD 2.49 billion.
In terms of R&D investment focus, BEONE MEDICINES R&D Expenses changed from USD 1.01 billion in the same period last year to USD 1.15 billion in the current period, increased by USD 146.72 million; R&D to Total Revenue Ratio changed from 41.39% in the same period last year to 35.84% in the current period, decreased by 5.55 percentage points.
By the close of trading on August 05, 2026, BEONE MEDICINES(06160) saw a gain of 2.63% in its share price, closing at HKD 198.7. During the session, it reached an intraday high of HKD 200.6. The full-day turnover stood at HKD 883.01 million, showing significant volume increase, with the latest market capitalization at HKD 283.59 billion.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
